Stoke Therapeutics (STOK) Price & Analysis

Compare

461 Followers

STOK Stock Chart & Stats

$22.47

-$0.34(-3.65%)

At close: Jan 08 4:00 PM EST

$22.47

-$0.34(-3.65%)

Day’s Range― - ―

52-Week Range$5.35 - $38.69

Previous CloseN/A

Volume337.58K

Average Volume (3M)1.40M

Market Cap

$1.30B

Enterprise Value$1.13B

Total Cash (Recent Filing)$248.31M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)34.0

Beta1.53

Next Earnings

Mar 11, 2026

EPS Estimate

-0.7

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.65

Shares Outstanding57,117,150

10 Day Avg. Volume1,120,950

30 Day Avg. Volume1,398,251

Financial Highlights & Ratios

PEG Ratio0.22

Price to Book (P/B)2.60

Price to Sales (P/S)16.30

P/FCF Ratio-6.84

Enterprise Value/Market Cap0.87

Enterprise Value/Revenue5.51

Enterprise Value/Gross Profit5.81

Enterprise Value/Ebitda39.58

Forecast

1Y Price Target

$29.75

Price Target Upside32.40% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering9

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Trial ProgressThe ongoing Phase 3 pivotal trial for the zorevunersen program in Dravet Syndrome appears to be progressing well and ahead of schedule.

Financial PerformanceSTOK reported 2Q25 total revenue $14M vs. consensus $9M, showing better than expected revenue performance.

Regulatory ApprovalSTOK plans to meet with the FDA to discuss potential avenues for an expedited approval pathway for zorevunersen in Dravet Syndrome.

Bears Say

Stoke Therapeutics News

Stoke Therapeutics price target raised to $28 from $24 at Canaccord

Canaccord raised the firm’s price target on Stoke Therapeutics (STOK) to $28 from $24 and keeps a Buy...

3d ago

STOK

Stoke Therapeutics reports Q3 EPS (65c), consensus (57c)

Reports Q3 revenue $10.6M, consensus $5.51M. “Stoke’s progress in 2025 has the Company on an important growth trajectory....

3d ago

STOK

Stoke Therapeutics price target raised to $25 from $15 at JPMorgan

JPMorgan raised the firm’s price target on Stoke Therapeutics (STOK) to $25 from $15 and keeps a Neutral...

5d ago

STOK

Stoke Therapeutics presents two-year data from FALCON study

Stoke Therapeutics (STOK) announced the presentation of two-year data from the FALCON study, a prospective natural history study...

19d ago

STOK

Stoke Therapeutics price target raised to $35 from $22 at Needham

Needham raised the firm’s price target on Stoke Therapeutics (STOK) to $35 from $22 and keeps a Buy...

29d ago

STOK

Biogen, Stoke Therapeutics present follow-up analyses from zorevunersen studies

Biogen (BIIB) and Stoke Therapeutics (STOK) announced the presentation of longer-term follow-up analyses from the ongoing open-label extension...

29d ago

BIIB

STOK

Stoke, Biogen presents new data from OLE studies of zorevunersen

Stoke Therapeutics (STOK) and Biogen (BIIB) announced the presentation of longer-term follow-up analyses from the ongoing open-label extension...

29d ago

BIIB

STOK

Positive Outlook for Stoke Therapeutics: Buy Rating Reinforced by Phase 3 Trial Progress and Regulatory Engagement

Analyst Joseph Stringer from Needham maintained a Buy rating on Stoke Therapeutics and keeping the price target at...

3d ago

STOK

Buy Rating for Stoke Therapeutics: Promising Potential of Zorevunersen in Dravet Syndrome Treatment

H.C. Wainwright analyst Ananda Ghosh has maintained their bullish stance on STOK stock, giving a Buy rating yesterday....

3d ago

STOK

Stoke Therapeutics: Promising Outlook with Breakthrough Therapy Designation and Strong Financial Position

BTIG analyst Thomas Shrader has maintained their bullish stance on STOK stock, giving a Buy rating yesterday. Thomas...

3d ago

STOK

Stoke Therapeutics Advances in RNA Medicine and Financial Growth

Stoke Therapeutics ( ($STOK) ) has released its Q3 earnings. Here is a breakdown of the information Stoke...

3d ago

STOK

Promising Potential and Strong Financial Position Drive Buy Rating for Stoke Therapeutics

TD Cowen analyst Yaron Werber has maintained their bullish stance on STOK stock, giving a Buy rating on...

3d ago

STOK

STOK Earnings this Week: How Will it Perform?

Stoke Therapeutics (STOK) is scheduled to report 3rd quarter earnings on 11/04/2025, after the market closes. Regarding Q3...

6d ago

STOK

Stoke Therapeutics Advances Phase 3 Study for Dravet Syndrome Treatment

Stoke Therapeutics (($STOK)) announced an update on their ongoing clinical study. Study Overview: The EMPEROR study is a...

11d ago

STOK

STOK FAQ

What was Stoke Therapeutics Inc’s price range in the past 12 months?

Stoke Therapeutics Inc lowest stock price was $5.35 and its highest was $38.69 in the past 12 months.

What is Stoke Therapeutics Inc’s market cap?

Stoke Therapeutics Inc’s market cap is $1.30B.

When is Stoke Therapeutics Inc’s upcoming earnings report date?

Stoke Therapeutics Inc’s upcoming earnings report date is Mar 11, 2026 which is in 123 days.

How were Stoke Therapeutics Inc’s earnings last quarter?

Stoke Therapeutics Inc released its earnings results on Nov 04, 2025. The company reported -$0.65 earnings per share for the quarter, missing the consensus estimate of -$0.568 by -$0.082.

Is Stoke Therapeutics Inc overvalued?

According to Wall Street analysts Stoke Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Stoke Therapeutics Inc pay dividends?

Stoke Therapeutics Inc does not currently pay dividends.

What is Stoke Therapeutics Inc’s EPS estimate?

Stoke Therapeutics Inc’s EPS estimate is -0.7.

How many shares outstanding does Stoke Therapeutics Inc have?

Stoke Therapeutics Inc has 57,117,150 shares outstanding.

What happened to Stoke Therapeutics Inc’s price movement after its last earnings report?

Stoke Therapeutics Inc reported an EPS of -$0.65 in its last earnings report, missing expectations of -$0.568. Following the earnings report the stock price went down -9.945%.

Which hedge fund is a major shareholder of Stoke Therapeutics Inc?

Currently, no hedge funds are holding shares in STOK

Stoke Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

15.02%

Trailing 12-Months

Asset Growth

22.82%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Stoke Therapeutics Inc

Stoke Therapeutics (STOK) is a biotechnology company focused on developing innovative RNA-based therapies to treat a range of severe genetic diseases. The company leverages its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform to enhance the expression of specific genes, aiming to restore protein levels that are insufficient in certain disorders. Stoke Therapeutics primarily operates in the biotechnology sector, with a focus on rare diseases, and is advancing its lead product candidates through clinical trials to address conditions like epilepsy and other neurological disorders.

Stoke Therapeutics (STOK) Earnings & Revenues

Historic Earnings Reports

STOK Company Deck

STOK Earnings Call

Q3 2025

0:00 / 0:00

STOK Stock 12 Month Forecast

Average Price Target

$29.75

▲(32.40% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","40":"$40","13.75":"$13.75","22.5":"$22.5","31.25":"$31.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":39,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$39.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":29.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$29.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$22.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,13.75,22.5,31.25,40],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,30.04,30.729230769230767,31.41846153846154,32.107692307692304,32.79692307692308,33.48615384615385,34.175384615384615,34.864615384615384,35.55384615384615,36.24307692307692,36.93230769230769,37.621538461538464,38.31076923076923,{"y":39,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,30.04,30.017692307692307,29.995384615384616,29.973076923076924,29.95076923076923,29.928461538461537,29.906153846153845,29.883846153846154,29.861538461538462,29.83923076923077,29.816923076923075,29.794615384615383,29.77230769230769,{"y":29.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,30.04,29.42153846153846,28.803076923076922,28.184615384615384,27.566153846153846,26.947692307692307,26.32923076923077,25.71076923076923,25.092307692307692,24.473846153846154,23.855384615384615,23.236923076923077,22.61846153846154,{"y":22,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":12.37,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.86,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.07,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.03,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.48,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.85,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.23,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.87,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.91,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.65,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.91,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.59,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.04,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >